CWI1-2 - ≥98% , CAS No.2408590-36-1

CAS: 2408590-36-1 Cat. No.: C647867 Molecular Weight: 519.77

GRADE & PURITY ≥98%

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Overview

CWI1-2 is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects.

In Vitro

CWI1-2 (0-1 μM, 24 h) has good anti-leukemic efficacy. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Apoptosis AnalysisCell Line: MonoMac6, MOLM13 Concentration: 0-1 μM Incubation Time: 24 h Result: Induced significant cell differentiation and apoptosis in a concentration-dependent manner in IGF2BP2-high cells but not in IGF2BP2-low cells. Reduced Gln uptake and impaired mitochondrial function, resulting in reduced ATP production in AML cells. Significantly inhibited the colony-forming ability of MA9-induced leukemic mouse blasts and greatly impairs the self-renewal of LSC/LIC.

In Vivo

CWI1-2 (5 mg/kg, i.v., once daily, 7-10 days) can significantly delay the onset of leukemia and prolong the survival time of BMT recipient B6.SJL (CD45.1) mice without any loss in body weight . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Form:Solid

Specifications

Specifications & Purity

≥98%

Biochemical and Physiological Mechanisms

CWI1-2 is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects.

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

This product requires cold chain shipping. Ground and other economy services are not available.

Purity

≥98%

Names and Identifiers

• Canonical Smiles: OC(C=C1)=C(C=C1Cl)/C=N/N=C(N/N=C\\C(C=C2Cl)=C(C=C2)O)\\N/N=C/C(C=C3Cl)=C(C=C3)O
• Molecular Weight: 519.77

Chemical and Physical Properties

• Solubility: DMSO : 100 mg/mL (192.39 mM; Need ultrasonic)